SCShauna Crampsie

Shauna Crampsie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shauna Crampsie has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epithelial Stem Cell Fate Determines Chemoradiotherapy Response in Rectal Cancer

    by Nick Li, Fiza Ishaqwala, Thomas A. Wright, Alistair Wilkinson, Petra Vlckova, Katherine Trevers, Rhianna O’SUllivan, Shauna Crampsie, Ewa Basiarz, Sierra Vanderkamp, et al.

    SUMMARY: Rectal cancers are often treated with neoadjuvant chemoradiotherapy (CRT), yet 85% of patients do not achieve a pathological complete response. To identify the molecular determinants of CRT response, we profiled the single-cell signalling, DNA-damage, cell-cycle, apoptotic, and cell-fate responses of 2,769 patient-derived organoid cultures treated with CRT, cancer-associated fibroblasts (CAFs), and signal-rewiring agents. We find that CRT response is determined by stem cell-fate. CRT triggers comparable DNA-damage in isogenic proliferative (proCSC) and revival (revCSC) colonic stem cells, but proCSC retain damage and die whereas revCSC resolve damage and persist. Both CRT and CAFs drive proCSC to a common treatment-resistant revCSC fate and high revCSC predicts worse survival in patients. Pharmacologically constraining stem-cell plasticity increases CRT sensitivity, and Spatial Perturbation of ARrayed Tumour Assembloids (SPARTA) confirms YAP/TEAD inhibition improves chemotherapy responses in human stromal-tumour models. These results suggest that cancer cell-fate, not genotoxic damage itself, ultimately governs response to standard-of-care chemoradiotherapy. HIGHLIGHTS: Rectal cancer stem cell-fate determines chemoradiotherapy-induced apoptosis proCSCs retain DNA-damage and die, whereas revCSCs repair damage and persist CAFs and chemoradiotherapy converge on a common chemo-radioresistant revCSC state SPARTA reveals TEAD inhibition blocks DNA-repair persisters in stromal assembloids

  • Open Access

    Stromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer

    by Christopher Tape, Corinne Molyneux, Rhianna O'SUllivan, Eoghan Mulholland-Illingworth, Joshua Moore, Nick Li, Petra Vlckova, Raheleh Amirkhah, Aurélie Dobric, Shauna Crampsie, et al.

    Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.

  • Open Access

    Stromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer

    by Corinne Molyneux, Rhianna O'SUllivan, Eoghan J. Mulholland-Illingworth, Joshua W. Moore, Nick Li, Petra Vlckova, Raheleh Amirkhah, Aurelie Dobric, Shauna Crampsie, Alistair Wilkinson, et al.

    Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.


  • Open Access

    A probabilistic histological atlas of the human brain for MRI segmentation

    by Adrià Casamitjana, Matteo Mancini, Eleanor Robinson, Loïc Peter, Roberto Annunziata, Juri Althonayan, Shauna Crampsie, Emily Blackburn, Benjamin Billot, Alessia Atzeni, et al.

    In human neuroimaging, brain atlases are essential for segmenting regions of interest (ROIs) and comparing subjects in a common coordinate frame. State-of-the-art atlases derived from histology1,2,3 provide exquisite three-dimensional cytoarchitectural maps but lack probabilistic labels throughout the whole brain: that is, the likelihood of each location belonging to a given ROI. Here we present NextBrain, a probabilistic histological atlas of the whole human brain. We developed artificial intelligence-enabled methods to align roughly 10,000 histological sections from five whole brain hemispheres into three-dimensional volumes and to produce delineations for 333 ROIs on these sections. We also created a companion Bayesian tool for automatic segmentation of these ROIs in magnetic resonance imaging (MRI) scans. We showcase two applications of the atlas: segmentation of ultra-high-resolution ex vivo MRI and volumetric analysis of Alzheimer’s disease using in vivo MRI. We publicly release raw and aligned data, an online visualization tool, the atlas, the segmentation tool, and ground truth delineations for a high-resolution ex vivo hemisphere used in validation. By enabling researchers worldwide to automatically analyse brain MRIs at a higher level of granularity, NextBrain holds promise to increase the specificity of findings and accelerate our quest to understand the human brain in health and disease.